Omer S Karrar (Omer Karrar)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 10

Top Topics

Acute Myeloid Leukemia

Allogeneic Hematopoietic Stem Cell Transplantation

Pulmonary Embolism

Tyrosine Kinase

Top Venues

American journal of hematology

Blood cancer journal

This page only lists publications with an associated author ORCID identifier.

Publications

Naseema Gangat, Omer S Karrar, Aref A Al-Kali, Kebede H Begna, Michelle A Elliott, Alexandra P Wolanskyj-Spinner, Animesh Pardanani, Curtis A Hanson, Rhett P Ketterling, Ayalew Tefferi
One thousand patients with essential thrombocythemia: the Mayo Clinic experience. Blood cancer journal 14 (1) (2024)
Naseema Gangat, Omer S Karrar, Aref A Al-Kali, Kebede H Begna, Michelle A Elliott, Alexandra P Wolanskyj-Spinner, Animesh Pardanani, Curtis A Hanson, Rhett P Ketterling, Ayalew Tefferi
One thousand patients with essential thrombocythemia: the Mayo Clinic experience. Blood cancer journal 14 (1) (2024)
Naseema Gangat, Omer S Karrar, Aref A Al-Kali, Kebede H Begna, Michelle A Elliott, Alexandra P Wolanskyj-Spinner, Animesh Pardanani, Curtis A Hanson, Rhett P Ketterling, Ayalew Tefferi
One thousand patients with essential thrombocythemia: the Mayo Clinic experience. Blood cancer journal 14 (1) (2024)
Naseema Gangat, Omer S Karrar, Aref A Al-Kali, Kebede H Begna, Michelle A Elliott, Alexandra P Wolanskyj-Spinner, Animesh Pardanani, Curtis A Hanson, Rhett P Ketterling, Ayalew Tefferi
One thousand patients with essential thrombocythemia: the Mayo Clinic experience. Blood cancer journal 14 (1) (2024)
Omer S Karrar, Maymona Abdelmagid, Masooma Rana, Moazah Iftikhar, McCullough Kristen, Aref A Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Michelle A Elliott, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Hefazi, Mark R Litzow, William Hogan, Mithun Vinod Shah, Mirinal S Patnaik, Animesh D Pardanani, Talha Badar, Hemant S Murthy, James Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y Arana Yi, Ayalew Tefferi, Naseema Gangat
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival. American journal of hematology 99 (2) (2023)
Naseema Gangat, Omer S Karrar, Moazah Iftikhar, McCullough Kristen, Isla M Johnson, Maymona Abdelmagid, Mostafa Abdallah, Aref A Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Hefazi, Mark R Litzow, William Hogan, Mithun Vinod Shah, Mirinal S Patnaik, Animesh D Pardanani, Talha Badar, Hemant S Murthy, James Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y Arana Yi, Ayalew Tefferi
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients. American journal of hematology (2023)
Omer S Karrar, Maymona Abdelmagid, Masooma Rana, Moazah Iftikhar, McCullough Kristen, Aref A Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Michelle A Elliott, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Hefazi, Mark R Litzow, William Hogan, Mithun Vinod Shah, Mirinal S Patnaik, Animesh D Pardanani, Talha Badar, Hemant S Murthy, James Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y Arana Yi, Ayalew Tefferi, Naseema Gangat
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival. American journal of hematology 99 (2) (2023)
Omer S Karrar, Maymona Abdelmagid, Masooma Rana, Moazah Iftikhar, McCullough Kristen, Aref A Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Michelle A Elliott, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Hefazi, Mark R Litzow, William Hogan, Mithun Vinod Shah, Mirinal S Patnaik, Animesh D Pardanani, Talha Badar, Hemant S Murthy, James Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y Arana Yi, Ayalew Tefferi, Naseema Gangat
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival. American journal of hematology (2023)
Maymona G Abdelmagid, Aref A Al-Kali, Mark R Litzow, Kebede H Begna, William Joseph Hogan, Mirinal S Patnaik, Shahrukh K. Hashmi, Michelle A Elliott, Hassan B Alkhateeb, Omer S Karrar, Farah Fleti, Mohammed H Elnayir, Candido E Rivera, Hemant S Murthy, James M Foran, Mohamed A Kharfan-Dabaja, Talha Badar, David S Viswanatha, Kaaren K Reichard, Naseema Gangat, Ayalew Tefferi
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events. Blood cancer journal 13 (1) (2023)
Omer S Karrar, Maymona Abdelmagid, Masooma Rana, Moazah Iftikhar, McCullough Kristen, Aref A Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Michelle A Elliott, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Hefazi, Mark R Litzow, William Hogan, Mithun Vinod Shah, Mirinal S Patnaik, Animesh D Pardanani, Talha Badar, Hemant S Murthy, James Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Y Arana Yi, Ayalew Tefferi, Naseema Gangat
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival. American journal of hematology 99 (2) (2023)